NIH scientists develop candidate vaccine against respiratory syncytial virus
Structure-based design may be key to successful vaccine for common childhood illness
An experimental vaccine to protect against respiratory syncytial virus (RSV), a leading cause of illness and hospitalization among very young children, elicited high levels of RSV-specific antibodies when tested in animals, according to a report in the journal Science.
This page was last updated on Friday, January 21, 2022